Linked Life Data

1078970

Source:http://linkedlifedata.com/resource/pubmed/id/1078970

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1975-5-29
pubmed:abstractText
Studies of circulating T- and B-lymphocyte rosettes were done in 20 healthy controls and 29 patients with pulmonary tuberculosis, including 18 receiving rifampin chemotherapy. Eight of the 18 patients in the rifampin group (44%) had significant suppression of their T-cell rosettes as compared with patients with tuberculosis not receiving rifampin (P less than 0.005). Seven of the eight patients with suppressed T-cell rosettes had received the drug for longer than 6 weeks. No significant difference was observed in circulating T- and B-lymphocyte rosettes between healthy controls and patients not receiving rifampin. Administration of this drug to two healthy subjects in a dosage of 600 mg daily for 28 days was associated with suppression of T-lymphocyte rosettes. The maximum decreases of 40% and 37% were observed at 14 and 21 days respectively, with return to base-line values within 2 weeks of discontinuation of drug therapy; this indicates complete reversibility. Long-term sequential studies will be required to determine whether T-cell suppression after prolonged therapy with rifampin is also reversible or associated with any harmful sequels.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0003-4819
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
484-8
pubmed:dateRevised
2009-10-27
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
Suppression of T-lymphocyte rosettes by rifampin. Studies in normals and patients with tuberculosis.
pubmed:publicationType
Journal Article